Close close

SEARCH

Enter your search term below:

WORLD LEADING BUSINESS SUPPORT

CASE STUDIES

View All

TRUEInvivo: Revolutionising radiotherapy with micro beads

TRUEInvivo: Revolutionising radiotherapy with micro beads

TRUEinvivo is revolutionising the success of radiotherapy treatments through its use of specially designed micro silica beads that can measure the exact dose of radiation a patient receives. The many advantages of this include better targeting of cancers, high confidence in dose accuracy, and a significant reduction in the damage of healthy tissue around the cancer. TRUEinvivo’s function does not just stop at medical applications however, the DOSEmapper™ technology has also been successfully used in nuclear areas, industrial applications, animal health, aerospace, blood banks and food irradiation.

TRUEInvivo: Revolutionising radiotherapy with micro beads

FACT FILE

Start date: 2014

Website: Visit website

Location: Surrey

Employees: 7

 

Innovation to Commercialisation of University Research (ICURe)

Funding: Grants: TBC; Equity: TBC

KEY MILESTONES

2013

Took part in ICURe

2017

Science proven in 20 hospitals

March 2017

First patent published

August 2019

Second patent published

September 2019

Beads accepted CE class 1 medical device

October 2019

£430k seed funding round closed

November 2019

Pre-production reader

January 2020

DOSEmapper™ & Automated Reader Patent granted in USA

January 2021

Patents granted in Europe

“I applied for the ICURe programme because I had discovered that silicon beads could be excellent radiation detectors with high precision dosimetry for radiotherapy patients. ICURe provided the help I needed to understand how I should go about commercialising my research. I realised that if I didn’t do this, the idea would just stay buried in a research paper, gathering dust in a library. ICURe really opened my eyes beyond academia.”

“With the funding from ICURe I was able to travel to all of the big conferences and radiotherapy centres around the world and talk to both customers and competitors. It gave me a deep understanding of the reality of the market far beyond everything I thought I knew from research papers. I think the ICURe programme needs to be mandated for every person who does research in applied fields. Being able to talk to individuals who are actually in practice and hearing them describe their problems first-hand was so valuable, you can really feel how much you can help.”

“As a result of the market validation, it turned my critical thinking into reality and confirmed that there was a gap in the market for my technology. What also came to light was that the challenges are not just technical, and in fact cultural bias plays a role in developing new products, particularly in the medical field. Accepting a new solution to how something has always been done is the hardest barrier to overcome.”

“What I learnt is that I have to show the medical communities what is possible with these new techniques. Following ICURe I started doing more and more research trials in hospitals and clinical settings, publishing papers and presenting in conferences, because that’s the way a medical physicist accepts change. Currently in advanced countries, up to 30% of patients do not receive the right dose of radiotherapy within recommended accuracy of ±5%, which causes damaging side effects and failure of the treatment. Our technology has an accuracy of +/- 3%, which is game changing.”

“The downside of a high precision reader such as ours is that finding a manufacturer to produce a prototype, for an affordable price, has been incredibly difficult. We chose a manufacturer we could afford, but as a result it has taken a lot longer than we had planned and the quality of product is not what we expected.”

“Our team has now grown to 7 people. Following ICURe I needed to bring on board people who could help me deliver on the business plan. My mentor at the University of Surrey, Mr. Nigel Biggs, joined the company as the CEO to allow me to focus on my strengths in the technicial capacity. Bringing in key hires to fill the commercial side of the business has allowed us to successfully pitch for investment and secure the funding we need.”

“The next step for us is to have a fully automatic reader. We have gone through the application of CE marking and we expect to have it approved imminently. Once we have that, we can offer our measuring beads and the automated reader as a pair to hospitals, who can then start to use them autonomously. What we have created has the potential to save lives. That thought alone has spurred me on through the difficult times – for thousands of people’s sakes, I can’t quit.”

Dr. Shakardokht Jafari

Dr. Shakardokht Jafari, Founder and CTO
TrueInvivo

SETsquared is a partnership between

  • University of Bath
  • University of Bristol
  • University of Exeter
  • University of Southampton
  • University of Surrey